Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Plasminogen activator inhibitor-1 promoter polymorphism is not associated with the aggressiveness of disease in prostate cancer.

Clinical oncology (Royal College of Radiologists (Great Britain)) - 1 May 2006

Li H, Shinohara E T, Cai Q, Chen H, Courtney R, Cao C, Wang Z, Teng M, Zheng W, Lu B

Abstract excerpt

AIMS: PAI-1 (plasminogen activator inhibitors-1) regulates plasminogen activation, and is related to tumour development. This study aims to test whether the promoter polymorphism in the PAI-1 gene is related to the aggressiveness of disease in prostate cancer. MATERIALS AND METHODS: In the present study, Taqman SNP genotyping assay was used to detect PAI-1 4G/5G polymorphism in DNA from paraffin-embedded tissues...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged, 80 and over
Share to Neoplasm Recurrence, Local

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Plasminogen Activator Inhibitor 1

Share to Prognosis

Share to Promoter Regions, Genetic

Share to Prostatic Neoplasms

Share to Risk Assessment

Share to Risk Factors

Source

Identifiers

PMID: 16703752
DOI: 10.1016/j.clon.2006.02.005

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Plasminogen activator inhibitor-1 promoter polymorphism is not associated with the aggressiveness of disease in prostate cancer.PMID 16703752Read ↗

E-cadherin promoter polymorphisms are not associated with the aggressiveness of prostate cancer in Caucasian patients.Semantic proximity Read ↗

Plasminogen activator inhibitor-1 (PAI-1) gene 4G/5G promoter polymorphism is not associated with breast cancer.Semantic proximity Read ↗

Polymorphisms in the AR and PSA genes as markers of susceptibility and aggressiveness in prostate cancer.Semantic proximity Read ↗

Clinical significance of a single nucleotide polymorphism and allelic imbalance of matrix metalloproteinase-1 promoter region in prostate cancer.Semantic proximity Read ↗

Plasminogen activator inhibitor type-1 (PAI-1) polymorphism 4G/5G is associated with prostate cancer among men with a positive family history.Semantic proximity Read ↗

Plasminogen activator inhibitor-1 gene polymorphism and colorectal cancer risk and prognosis.Semantic proximity Read ↗

Plasminogen activator inhibitor 1 (PAI-1) levels and gene promoter polymorphisms in subjects with colorectal cancer.Semantic proximity Read ↗

Single nucleotide polymorphisms and haplotypes in the gene for vascular endothelial growth factor and risk of prostate cancer.Semantic proximity Read ↗

Clinicopathological significance of plasminogen activator inhibitor-1 promoter 4G/5G polymorphism in breast cancer: a meta-analysis.Semantic proximity Read ↗

Role of MMP-1 1G/2G promoter gene polymorphism on the development of prostate cancer in the Turkish population.Semantic proximity Read ↗

Plasminogen activator inhibitor-1 4G/5G polymorphism in breast cancer patients and its association with tissue PAI-1 levels and tumor severity.Semantic proximity Read ↗

Polymorphisms in the prostate-specific antigen gene promoter do not predict serum prostate-specific antigen levels in African-American men.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.